MItochondrial Intervention for Resilience in Older Adults With Coenzyme Q10

Sponsor
University Medical Centre Ljubljana
Study ID
NCT07772336
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Aging
  • Frailty
  • Mitochondria Health
  • Mitochondrial Dysfunction
  • Skin Aging

Eligibility Criteria

Sex
ALL
Age
65 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Q10Vital® (CoQ10, ubiquinone) — DIETARY_SUPPLEMENT
    Participants randomized to the intervention group will receive Q10Vital®, a CoQ10 formulation containing ubiquinone in a β-cyclodextrin complex designed to improve solubility and oral bioavailability. Participants will take 200 mg of CoQ10 once daily for 10 weeks. The intervention will be administered orally according to the study protocol. Q10Vital® has demonstrated improved bioavailability compared with standard crystalline ubiquinone and bioavailability comparable to ubiquinol in previous pharmacokinetic research. The intervention is intended to increase systemic CoQ10 availability and assess its potential effects on mitochondrial functional resilience and related biological and clinical measures of aging.
  • Placebo — OTHER
    Participants randomized to the control group will receive a matching placebo once daily for 10 weeks. The placebo will be identical or sufficiently similar in appearance, packaging, administration schedule, and dosage form to the Q10Vital® intervention to maintain blinding throughout the study. The placebo will contain no active CoQ10 ingredient. Participants will take the placebo orally according to the same schedule as the active intervention.

Study Details

This randomized, double-blind, placebo-controlled clinical trial will investigate whether 10 weeks of CoQ10 supplementation can improve biological resilience and functional health in community-dwelling adults aged 65 years or older with signs of reduced biological resilience or prefrailty. Participants will be randomly assigned in a 1:1 ratio to receive either 200 mg of CoQ10 daily or matching placebo for 10 weeks. The study will assess the effects of CoQ10 supplementation on mitochondrial functional resilience, chronic low-grade inflammation, metabolic health, physical performance, cognitive function, and objective measures of skin aging. The study will also investigate whether baseline biological and functional characteristics can identify individuals who are more likely to benefit from CoQ10 supplementation. An exploratory aim is to develop a multidimensional composite index of biological resilience integrating molecular, biochemical, functional, and clinical measures of aging. The study will provide evidence on whether a mitochondria-targeted intervention with CoQ10 may represent a potential strategy for improving functional resilience and reducing features of prefrailty in older adults.

Key Dates

First listed
Aug 19, 2026
Start date
Sep 30, 2026
Status verified
Aug 2026
Primary completion
Dec 31, 2026
Completion
Feb 28, 2027

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: CoQ10
    CoQ10 - 200 mg daily for 10 weeks
  • Placebo Comparator: Placebo
    Matching placebo for 10 weeks

Primary Outcome Measure

Change in plasma GDF-15 concentration [ Time Frame: Baseline to Week 10 ]

Central Contacts

Related Studies